Could an arthritis drug spark motivation in schizophrenia?

NCT ID NCT05823532

Recruiting now Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether infliximab, an anti-inflammatory drug used for arthritis, can improve motivation and brain activity in people with schizophrenia who have high inflammation. Sixty adults with schizophrenia will receive either infliximab or a placebo, and researchers will measure changes in brain scans and motivation tasks. The goal is to see if reducing inflammation helps with the lack of motivation that many patients experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Infliximab
What this could lead to: If it works, this could point toward a new way to treat motivational problems in schizophrenia by reducing inflammation.
What could go wrong: This is a small early-phase study with only 60 people, so results may not apply widely. Infliximab can have serious side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Grady Memorial Hospital
RECRUITING

Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.